Brief: Adamis Pharmaceuticals Announces Leadership Transition To Support New Phase Of Innovation And Growth
18/05/2022 23:10
May 18 (Reuters) - Adamis Pharmaceuticals Corp ADMP.O :
* ADAMIS PHARMACEUTICALS ANNOUNCES LEADERSHIP TRANSITION TO
SUPPORT NEW PHASE OF INNOVATION AND GROWTH
* ADAMIS PHARMACEUTICALS CORP - DAVID J. MARGUGLIO,
CO-FOUNDER AND
CHIEF BUSINESS OFFICER, APPOINTED PRESIDENT AND CEO
* ADAMIS PHARMACEUTICALS CORP - DENNIS J. CARLO, PH.D., HAS
RETIRED AS BOTH CEO AND BOARD DIRECTOR
Source text for Eikon: ID:nGNX316BFw
Further company coverage: ADMP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on DMK Pharmaceuticals
See all newsBrief: Dmk Pharmaceuticals Corp Says Ebrahim Versi Resigned As Chairman
Brief: ZMI Pharma Finalized Acquisition Of All Strategic Assets Necessary To Manufacture Zimhi From Dmk Pharma
Brief: DMK Pharmaceuticals Files For Chapter 11 Bankruptcy In The U.S. - Court Filing
Brief: Dmk Pharmaceuticals Regains Full Rights To Commercialize Zimhi
Brief: DMK Pharmaceuticals Regains Full Rights From US Worldmeds For Symjepi And Provides Corporate Update